Pub Date : 2022-05-01Epub Date: 2022-04-07DOI: 10.1016/S1470-2045(22)00145-0
Paul T R Thiruchelvam, Daniel R Leff, Amy R Godden, Susan Cleator, Simon H Wood, Anna M Kirby, Navid Jallali, Navita Somaiah, Judith E Hunter, Francis P Henry, Aikaterini Micha, Rachel L O'Connell, Kabir Mohammed, Neill Patani, Melissa L H Tan, Dorothy Gujral, Gillian Ross, Stuart E James, Aadil A Khan, Jennifer E Rusby, Dimitri J Hadjiminas, Fiona A MacNeill
Background: Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. However, evidence for this treatment sequence is sparse. We aimed to explore the feasibility of preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction in patients with breast cancer requiring mastectomy.
Methods: We conducted a prospective, non-randomised, feasibility study at two National Health Service trusts in the UK. Eligible patients were women aged older than 18 years with a laboratory diagnosis of primary breast cancer requiring mastectomy and post-mastectomy radiotherapy, who were suitable for DIEP flap reconstruction. Preoperative radiotherapy started 3-4 weeks after neoadjuvant chemotherapy and was delivered to the breast, plus regional nodes as required, at 40 Gy in 15 fractions (over 3 weeks) or 42·72 Gy in 16 fractions (over 3·2 weeks). Adverse skin radiation toxicity was assessed preoperatively using the Radiation Therapy Oncology Group toxicity grading system. Skin-sparing mastectomy and DIEP flap reconstruction were planned for 2-6 weeks after completion of preoperative radiotherapy. The primary endpoint was the proportion of open breast wounds greater than 1 cm width requiring a dressing at 4 weeks after surgery, assessed in all participants. This study is registered with ClinicalTrials.gov, NCT02771938, and is closed to recruitment.
Findings: Between Jan 25, 2016, and Dec 11, 2017, 33 patients were enrolled. At 4 weeks after surgery, four (12·1%, 95% CI 3·4-28·2) of 33 patients had an open breast wound greater than 1 cm. One (3%) patient had confluent moist desquamation (grade 3). There were no serious treatment-related adverse events and no treatment-related deaths.
Interpretation: Preoperative radiotherapy followed by skin-sparing mastectomy and immediate DIEP flap reconstruction is feasible and technically safe, with rates of breast open wounds similar to those reported with post-mastectomy radiotherapy. A randomised trial comparing preoperative radiotherapy with post-mastectomy radiotherapy is required to precisely determine and compare surgical, oncological, and breast reconstruction outcomes, including quality of life.
Funding: Cancer Research UK, National Institute for Health Research.
背景：在乳房切除术和自体游离瓣乳房重建术前进行放疗，可避免对健康供体组织造成不良辐射影响，也可避免延误辅助放疗。然而，这种治疗顺序的证据并不多。我们的目的是探讨需要进行乳房切除术的乳腺癌患者术前放疗后进行保皮乳房切除术和深下上腹部穿孔器（DIEP）皮瓣重建的可行性：我们在英国两家国民健康服务托管机构开展了一项前瞻性、非随机、可行性研究。符合条件的患者是年龄大于 18 岁、实验室诊断为原发性乳腺癌、需要进行乳房切除术和乳房切除术后放疗、适合进行 DIEP 皮瓣重建术的女性。术前放疗在新辅助化疗后3-4周开始，对乳房及必要的区域结节进行放疗，剂量为40 Gy，15次/分（3周）或42-72 Gy，16次/分（3-2周）。术前采用肿瘤放疗组毒性分级系统对皮肤放射毒性进行评估。计划在术前放疗结束后2-6周进行保皮乳房切除术和DIEP皮瓣重建术。主要终点是所有参与者术后4周时需要敷料的乳房开放性伤口宽度大于1厘米的比例。该研究已在ClinicalTrials.gov注册，编号为NCT02771938，目前已结束招募：2016年1月25日至2017年12月11日期间，33名患者入组。术后4周，33名患者中有4人（12-1%，95% CI 3-4-28-2）的乳房开放性伤口大于1厘米。1名患者（3%）出现汇合性湿性脱屑（3级）。没有发生与治疗相关的严重不良事件，也没有发生与治疗相关的死亡事件：术前放疗后行乳房皮肤保留切除术和即刻DIEP皮瓣重建术是可行的，技术上也是安全的，乳房开放性伤口的发生率与乳房切除术后放疗的发生率相似。需要进行一项随机试验，比较术前放疗和乳房切除术后放疗，以精确确定和比较手术、肿瘤学和乳房重建的结果，包括生活质量：资金来源：英国癌症研究中心、英国国家健康研究所。
{"title":"Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study.","authors":"Paul T R Thiruchelvam, Daniel R Leff, Amy R Godden, Susan Cleator, Simon H Wood, Anna M Kirby, Navid Jallali, Navita Somaiah, Judith E Hunter, Francis P Henry, Aikaterini Micha, Rachel L O'Connell, Kabir Mohammed, Neill Patani, Melissa L H Tan, Dorothy Gujral, Gillian Ross, Stuart E James, Aadil A Khan, Jennifer E Rusby, Dimitri J Hadjiminas, Fiona A MacNeill","doi":"10.1016/S1470-2045(22)00145-0","DOIUrl":"10.1016/S1470-2045(22)00145-0","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. However, evidence for this treatment sequence is sparse. We aimed to explore the feasibility of preoperative radiotherapy followed by skin-sparing mastectomy and deep inferior epigastric perforator (DIEP) flap reconstruction in patients with breast cancer requiring mastectomy.</p><p><strong>Methods: </strong>We conducted a prospective, non-randomised, feasibility study at two National Health Service trusts in the UK. Eligible patients were women aged older than 18 years with a laboratory diagnosis of primary breast cancer requiring mastectomy and post-mastectomy radiotherapy, who were suitable for DIEP flap reconstruction. Preoperative radiotherapy started 3-4 weeks after neoadjuvant chemotherapy and was delivered to the breast, plus regional nodes as required, at 40 Gy in 15 fractions (over 3 weeks) or 42·72 Gy in 16 fractions (over 3·2 weeks). Adverse skin radiation toxicity was assessed preoperatively using the Radiation Therapy Oncology Group toxicity grading system. Skin-sparing mastectomy and DIEP flap reconstruction were planned for 2-6 weeks after completion of preoperative radiotherapy. The primary endpoint was the proportion of open breast wounds greater than 1 cm width requiring a dressing at 4 weeks after surgery, assessed in all participants. This study is registered with ClinicalTrials.gov, NCT02771938, and is closed to recruitment.</p><p><strong>Findings: </strong>Between Jan 25, 2016, and Dec 11, 2017, 33 patients were enrolled. At 4 weeks after surgery, four (12·1%, 95% CI 3·4-28·2) of 33 patients had an open breast wound greater than 1 cm. One (3%) patient had confluent moist desquamation (grade 3). There were no serious treatment-related adverse events and no treatment-related deaths.</p><p><strong>Interpretation: </strong>Preoperative radiotherapy followed by skin-sparing mastectomy and immediate DIEP flap reconstruction is feasible and technically safe, with rates of breast open wounds similar to those reported with post-mastectomy radiotherapy. A randomised trial comparing preoperative radiotherapy with post-mastectomy radiotherapy is required to precisely determine and compare surgical, oncological, and breast reconstruction outcomes, including quality of life.</p><p><strong>Funding: </strong>Cancer Research UK, National Institute for Health Research.</p>","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":"9 1","pages":"682-690"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90106095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Fardaei, S. Tabei, S. Ghafouri-Fard, M. Miryounesi
A New Mutation in WT1 Gene Associated with Wilms Tumor with Reduced Penetrance in an Iranian Family Majid Fardaei, Seyed Mohammad Bagher Tabei, Soudeh Ghafouri-Fard, and Mohammad Miryounesi Department of Medical Genetics, Shiraz University of Medical sciences, Shiraz, IR Iran Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran Corresponding author: Soudeh Ghafouri-Fard, Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2122439959, E-mail: s.ghafourifard@sbmu.ac.ir Corresponding author: Mohammad Miryounesi, Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2122439959, E-mail: miryounesi@gmail.com
{"title":"A New Mutation in WT1 Gene Associated with Wilms Tumor with Reduced Penetrance in an Iranian Family","authors":"M. Fardaei, S. Tabei, S. Ghafouri-Fard, M. Miryounesi","doi":"10.5812/IJCM.7500","DOIUrl":"https://doi.org/10.5812/IJCM.7500","url":null,"abstract":"A New Mutation in WT1 Gene Associated with Wilms Tumor with Reduced Penetrance in an Iranian Family Majid Fardaei, Seyed Mohammad Bagher Tabei, Soudeh Ghafouri-Fard, and Mohammad Miryounesi Department of Medical Genetics, Shiraz University of Medical sciences, Shiraz, IR Iran Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran Corresponding author: Soudeh Ghafouri-Fard, Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2122439959, E-mail: s.ghafourifard@sbmu.ac.ir Corresponding author: Mohammad Miryounesi, Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2122439959, E-mail: miryounesi@gmail.com","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":"10 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2017-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47547144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seideh Zeinab Almasi, H. Salehiniya, Neda Amoori, S. Mahdavi, M. Enayatrad
{"title":"Trends in the Incidence of Cancer in Iran (2003 - 2009)","authors":"Seideh Zeinab Almasi, H. Salehiniya, Neda Amoori, S. Mahdavi, M. Enayatrad","doi":"10.5812/IJCP.4715","DOIUrl":"https://doi.org/10.5812/IJCP.4715","url":null,"abstract":"","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41425771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: To study overall and province-specific trends of bladder cancer incidence in Iran during 2004-2008 and to evaluate the association between bladder cancer incidence and some factors. Methods: Data on 17792 bladder cancer patients and risk factors available at province level were used in Bayesian ecological setting. First, the overall and province-specific trends of risk were estimated. Then the effects of cigarette smoking, being overweight, fruits and vegetables consumption, and low levels of physical activity on trend were examined. The province-specific effects of significant factors were also assessed. The data were analyzed using R-INLA package. Results: The risk of developing bladder cancer was decreasing in Iran, 2004 - 2008 (RR = 0.95). Guilan and Semnan had the highest 5-year incidence (RR > 1.5). However, the risk increase compared to country Risk was the highest in East Azerbaijan and Tehran (DT > 0.1). Also direct and reverse association between smoking and fruit consumption and bladder cancer risk were established. Guilan, Semnan, Sistan and Baluchestan, and Ilam were the provinces affected the most by these factors. Conclusions: This study confirms previous findings and provides further evidence on protective effects of fruit consumption in bladder cancer. The results would be of value for governors to prioritize the province-specific demands on research, education, and improvements with respect to the identified risk factors.
{"title":"Bladder Cancer in Iran: Geographical Distribution and Risk Factors","authors":"T. Jafari-Koshki, S. Arsang-Jang, B. Mahaki","doi":"10.5812/IJCP.5610","DOIUrl":"https://doi.org/10.5812/IJCP.5610","url":null,"abstract":"Background: To study overall and province-specific trends of bladder cancer incidence in Iran during 2004-2008 and to evaluate the association between bladder cancer incidence and some factors. Methods: Data on 17792 bladder cancer patients and risk factors available at province level were used in Bayesian ecological setting. First, the overall and province-specific trends of risk were estimated. Then the effects of cigarette smoking, being overweight, fruits and vegetables consumption, and low levels of physical activity on trend were examined. The province-specific effects of significant factors were also assessed. The data were analyzed using R-INLA package. Results: The risk of developing bladder cancer was decreasing in Iran, 2004 - 2008 (RR = 0.95). Guilan and Semnan had the highest 5-year incidence (RR > 1.5). However, the risk increase compared to country Risk was the highest in East Azerbaijan and Tehran (DT > 0.1). Also direct and reverse association between smoking and fruit consumption and bladder cancer risk were established. Guilan, Semnan, Sistan and Baluchestan, and Ilam were the provinces affected the most by these factors. Conclusions: This study confirms previous findings and provides further evidence on protective effects of fruit consumption in bladder cancer. The results would be of value for governors to prioritize the province-specific demands on research, education, and improvements with respect to the identified risk factors.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45170962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Akhavan, Z. Kazemi, A. Alibakhshi, M. Modaresgilani, A. Mousavi, A. Ahmadzadeh, Khadije Rezaie Kahkhayi
Background: Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology and obstetrics (FIGO) staging system for risk stratification. Objectives: We aimed to investigate the prognostic significance of positive peritoneal cytology (PPC) in patients with early stage endometrioid adenocarcinoma. Methods: Medical profiles of patients with uterine carcinoma referring to Imam Khomeini hospital and Mirza Koochak Khan hospital between September, 2005 and December, 2011 have been reviewed. Patients had a complete staging procedure and peritoneal cytology evaluation. Results: Among 220 patients with mean age of 56.3 ± 9.1 years, 204 were Negative for peritoneal cytology (NPC) and 16 showed PPC. In the group of patients with endometrioid adenocarcinoma, 125 were in stage I and 32 were in stage II. Univariate analysis on patients with endometrioid adenocacinoma revealed that stage II (OR = 7.12, 95% CI = 2.95-22.10, P value < 0.001), stage III (OR = 8.04, 95% CI = 2.14 - 30.09, P value < 0.001), stage IV (OR = 58.09, 95% CI = 13.74 - 245.66, P value < 0.001), recurrence of either intra (OR = 32.65, 95% CI = 12.2 - 86.7, P value < 0.001) or extra pelvic (OR = 14.54, 95% CI = 4.4 - 47.7, P value < 0.001), and the number of lymph nodes involvement (OR = 5.59, 95% CI = 2.5 - 12.51, P value < 0.001) were significantly associated with survival. Also, patients with PPC had significantly poorer survival compared to those with negative peritoneal cytology; 38% Vs 88% were alive after 5 years (P value < 0.0001). Mean 5-year survival in PPC and NPC patients were 3.31 years and 4.74 years, respectively. Conclusions: Our study demonstrated that positive peritoneal cytology is an independent prognostic factor in patients with early stage endometrioid adenocarcinoma. We propound that peritoneal cytology adds back into the future FIGO staging criteria revision. Until then, peritoneal washings should still be considered as an important part for accurate risk-stratification.
{"title":"Positive Peritoneal Cytology as a Predictor of Prognosis in Early Stage of Endometrioid Adenocarcinoma","authors":"S. Akhavan, Z. Kazemi, A. Alibakhshi, M. Modaresgilani, A. Mousavi, A. Ahmadzadeh, Khadije Rezaie Kahkhayi","doi":"10.5812/IJCP.5285","DOIUrl":"https://doi.org/10.5812/IJCP.5285","url":null,"abstract":"Background: Peritoneal cytology has been reported to be an independent risk factor for poor survival, but it is not included in the current international federation of gynecology and obstetrics (FIGO) staging system for risk stratification. Objectives: We aimed to investigate the prognostic significance of positive peritoneal cytology (PPC) in patients with early stage endometrioid adenocarcinoma. Methods: Medical profiles of patients with uterine carcinoma referring to Imam Khomeini hospital and Mirza Koochak Khan hospital between September, 2005 and December, 2011 have been reviewed. Patients had a complete staging procedure and peritoneal cytology evaluation. Results: Among 220 patients with mean age of 56.3 ± 9.1 years, 204 were Negative for peritoneal cytology (NPC) and 16 showed PPC. In the group of patients with endometrioid adenocarcinoma, 125 were in stage I and 32 were in stage II. Univariate analysis on patients with endometrioid adenocacinoma revealed that stage II (OR = 7.12, 95% CI = 2.95-22.10, P value < 0.001), stage III (OR = 8.04, 95% CI = 2.14 - 30.09, P value < 0.001), stage IV (OR = 58.09, 95% CI = 13.74 - 245.66, P value < 0.001), recurrence of either intra (OR = 32.65, 95% CI = 12.2 - 86.7, P value < 0.001) or extra pelvic (OR = 14.54, 95% CI = 4.4 - 47.7, P value < 0.001), and the number of lymph nodes involvement (OR = 5.59, 95% CI = 2.5 - 12.51, P value < 0.001) were significantly associated with survival. Also, patients with PPC had significantly poorer survival compared to those with negative peritoneal cytology; 38% Vs 88% were alive after 5 years (P value < 0.0001). Mean 5-year survival in PPC and NPC patients were 3.31 years and 4.74 years, respectively. Conclusions: Our study demonstrated that positive peritoneal cytology is an independent prognostic factor in patients with early stage endometrioid adenocarcinoma. We propound that peritoneal cytology adds back into the future FIGO staging criteria revision. Until then, peritoneal washings should still be considered as an important part for accurate risk-stratification.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46157873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Esfandiary, A. Abedin-Do, Z. Taherian-Esfahani, S. Ghafouri-Fard, E. Motevaseli
{"title":"Intact Expression of Hypoxia-Inducible Factor 1α (HIF-1α) Gene in HeLa Cell Line Following Treatment with Lactobacilli Supernatants","authors":"A. Esfandiary, A. Abedin-Do, Z. Taherian-Esfahani, S. Ghafouri-Fard, E. Motevaseli","doi":"10.5812/IJCP.4774","DOIUrl":"https://doi.org/10.5812/IJCP.4774","url":null,"abstract":"","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":"10 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49293617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Montazer, F. Nemati, F. Dehghani, Tahereh Fallah
Background: Breast cancer is one of the most serious diseases that can endanger physical, psychological, and social health of women suffering from this disease. Objectives: The aim of this study was to evaluate the effectiveness of commitment and acceptance (ACT) on breast cancer patients’ hope. Methods: This quasi-experimental study included all patients with breast cancer who were inhibited in Yazd, Iran. Using convenience sampling, 34 patients were selected and randomly divided into two groups: the treatment group and the control group. Both groups completed Miller’s questionnaire on hope. Treatment group received psychological therapy of ACT for 12 weeks, 3 hours per week. Miller’s questionnaire was redistributed and completed again by both groups after completion of the treatment. The collected data were analyzed by SPSS software and running analysis of covariance. Results: The results of the current study revealed significant differences between control and treatment groups in terms of pre-test and post-test scores (P = 0.05). Conclusions: According to the results of the present study, psychological therapy of ACT can be useful in promoting the breast cancer patients’ hope.
{"title":"Efficacy of Acceptance and Commitment Therapy on Breast Cancer Female Patients’ Hope","authors":"A. Montazer, F. Nemati, F. Dehghani, Tahereh Fallah","doi":"10.5812/IJCP.5526","DOIUrl":"https://doi.org/10.5812/IJCP.5526","url":null,"abstract":"Background: Breast cancer is one of the most serious diseases that can endanger physical, psychological, and social health of women suffering from this disease. Objectives: The aim of this study was to evaluate the effectiveness of commitment and acceptance (ACT) on breast cancer patients’ hope. Methods: This quasi-experimental study included all patients with breast cancer who were inhibited in Yazd, Iran. Using convenience sampling, 34 patients were selected and randomly divided into two groups: the treatment group and the control group. Both groups completed Miller’s questionnaire on hope. Treatment group received psychological therapy of ACT for 12 weeks, 3 hours per week. Miller’s questionnaire was redistributed and completed again by both groups after completion of the treatment. The collected data were analyzed by SPSS software and running analysis of covariance. Results: The results of the current study revealed significant differences between control and treatment groups in terms of pre-test and post-test scores (P = 0.05). Conclusions: According to the results of the present study, psychological therapy of ACT can be useful in promoting the breast cancer patients’ hope.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45091506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Combination cancer therapy is a promising strategy which employs multiple therapeutic agents with different mechanisms of action along with minimal intolerable side effects. For example, a combination of radiotherapy with gene therapy can overcome the development of resistance to therapeutic doses of irradiation (IR) and normal tissue damages caused by high-dose radiation. Recent studies have revealed radio-resistance in non-small cell lung cancer (NSCLC) cells. In this study, for the first time, subunit B of cytolethal distending toxin (cdtB)-expressing plasmid was introduced as a sensitizer of the cells to IR with a high efficacy. Methods: A vector expressing cdtB suicide gene of human periodontal bacterium Aggregatibacter actinomycetemcomitans was constructed and then transfected into A549 cell line. In the next step, cells transfected with pcDNA3.1/cdtB were irradiated and its growth inhibitory effect was evaluated in NSCLC cancer in vitro by MTT (3-(4, 5-methylthiazol-2-yl) -2, 5-diphenyl-tetrazolium bromide) assay. Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were carried out in order to examine the apoptosis induction by a combination of IR with cdtB. Results: Our data indicated significant cell death in NSCLC cells in comparison with controls with an increase from 5% in response to IR up to 73.27% for combination of IR with cdtB. Moreover, the result of TUNEL assay showed significant differences in the number of apoptotic cells among the different affected groups. Conclusions: Our results confirmed that cdtB-expressing plasmid sensitizes NSCLC cells to IR and significantly increases the efficacy of radiotherapy and therefore, combining toxin with IR has a synergistic effect on NSCLC.
{"title":"Sensitization of Radio-Resistant Lung Cancer Cells with a B Subunit of Bacterial Cytolethal Distending Toxin from Aggregatibacter actinomycetemcomitans","authors":"H. Yaghoobi, B. Kazemi, M. Bandehpour","doi":"10.5812/IJCP.5792","DOIUrl":"https://doi.org/10.5812/IJCP.5792","url":null,"abstract":"Background: Combination cancer therapy is a promising strategy which employs multiple therapeutic agents with different mechanisms of action along with minimal intolerable side effects. For example, a combination of radiotherapy with gene therapy can overcome the development of resistance to therapeutic doses of irradiation (IR) and normal tissue damages caused by high-dose radiation. Recent studies have revealed radio-resistance in non-small cell lung cancer (NSCLC) cells. In this study, for the first time, subunit B of cytolethal distending toxin (cdtB)-expressing plasmid was introduced as a sensitizer of the cells to IR with a high efficacy. Methods: A vector expressing cdtB suicide gene of human periodontal bacterium Aggregatibacter actinomycetemcomitans was constructed and then transfected into A549 cell line. In the next step, cells transfected with pcDNA3.1/cdtB were irradiated and its growth inhibitory effect was evaluated in NSCLC cancer in vitro by MTT (3-(4, 5-methylthiazol-2-yl) -2, 5-diphenyl-tetrazolium bromide) assay. Terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were carried out in order to examine the apoptosis induction by a combination of IR with cdtB. Results: Our data indicated significant cell death in NSCLC cells in comparison with controls with an increase from 5% in response to IR up to 73.27% for combination of IR with cdtB. Moreover, the result of TUNEL assay showed significant differences in the number of apoptotic cells among the different affected groups. Conclusions: Our results confirmed that cdtB-expressing plasmid sensitizes NSCLC cells to IR and significantly increases the efficacy of radiotherapy and therefore, combining toxin with IR has a synergistic effect on NSCLC.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49101459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Allahyari, N. Esfandiari, F. Nazemian, M. Sadeghi
Introduction: The coexistence of B-cell chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in the same patient is rare. The aim of this study is to report of simultaneous occurrence of CLL and AML M5 in an old female patient for the first time. Case Presentation: A 72-year-old woman referred to hematology clinic for evaluation of leukocytosis, anemia, and thrombocytopenia. She had no known history of chronic illness or exposure to radiation or myelotoxic drugs. Physical examination showed the existence of generalized lymphadenopathy and splenomegaly. Section of the biopsy core disclosed a diffuse infiltration of lymphoid cells with hyperchromic irregular nuclei and scant cytoplasm in the background. Immunohistochemical staining for CD20 in lymphoid cells and CD68 in blastic cells were positive but it was negative for terminal deoxynucleotidyl transferase (TdT). The flow cytometric immunophenotyping analysis was performed in the presence of CD5 positive B-cell population (CD19; CD20 dim; CD23 and CD5/CD19) with small cell size that comprised 76% of cells with abnormal phenotype was revealed. Simultaneous occurrence of CLL and AML M5 was confirmed in the patients. Conclusions: We report a case of previously untreated CLL and AML M5 with rapidly progressive course to death in less than one month from diagnosis. To the best of our knowledge, the development of AML M5 in patient with CLL has not been reported before.
{"title":"Simultaneous Occurrence of B-Cell Lymphocytic Leukemia and Acute Myeloid Leukemia in an Elderly Female Patient","authors":"A. Allahyari, N. Esfandiari, F. Nazemian, M. Sadeghi","doi":"10.5812/IJCP.4930","DOIUrl":"https://doi.org/10.5812/IJCP.4930","url":null,"abstract":"Introduction: The coexistence of B-cell chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in the same patient is rare. The aim of this study is to report of simultaneous occurrence of CLL and AML M5 in an old female patient for the first time. Case Presentation: A 72-year-old woman referred to hematology clinic for evaluation of leukocytosis, anemia, and thrombocytopenia. She had no known history of chronic illness or exposure to radiation or myelotoxic drugs. Physical examination showed the existence of generalized lymphadenopathy and splenomegaly. Section of the biopsy core disclosed a diffuse infiltration of lymphoid cells with hyperchromic irregular nuclei and scant cytoplasm in the background. Immunohistochemical staining for CD20 in lymphoid cells and CD68 in blastic cells were positive but it was negative for terminal deoxynucleotidyl transferase (TdT). The flow cytometric immunophenotyping analysis was performed in the presence of CD5 positive B-cell population (CD19; CD20 dim; CD23 and CD5/CD19) with small cell size that comprised 76% of cells with abnormal phenotype was revealed. Simultaneous occurrence of CLL and AML M5 was confirmed in the patients. Conclusions: We report a case of previously untreated CLL and AML M5 with rapidly progressive course to death in less than one month from diagnosis. To the best of our knowledge, the development of AML M5 in patient with CLL has not been reported before.","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48767268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yaser Arjeyni, H. Goudarzi, G. Eslami, E. Faghihloo
Context: Cancers are among the gravest causes of the intensive immunodeficiency and provide favorable conditions for severe respiratory tract infections. Evidence Acquisition: Using various keywords related to the subject matter, articles were analyzed in PubMed and appropriately selected for review. Results: Inpatientswithcancer,someviralrespiratoryinfectionssuchasHRSV,Influenzavirus,HCMV,HMPVandHPIVareprevalent. Conclusions: Viral respiratory infections in cancer patients are common and can worsen the patients’ condition and disrupt the treatment process. Therefore, prevention and treatment of respiratory viral infections in cancer patients is important. rhesus monkey (RMK), MRC-5 antibody (DFA) testing, viral culture and real time RT-PCR. Twenty-four influenza infected pediatric cancer patients (20 influenza A and 4 influenza B cases) 27 clinical
{"title":"Viral Respiratory Infections in Patients with Cancer","authors":"Yaser Arjeyni, H. Goudarzi, G. Eslami, E. Faghihloo","doi":"10.5812/IJCP.8084","DOIUrl":"https://doi.org/10.5812/IJCP.8084","url":null,"abstract":"Context: Cancers are among the gravest causes of the intensive immunodeficiency and provide favorable conditions for severe respiratory tract infections. Evidence Acquisition: Using various keywords related to the subject matter, articles were analyzed in PubMed and appropriately selected for review. Results: Inpatientswithcancer,someviralrespiratoryinfectionssuchasHRSV,Influenzavirus,HCMV,HMPVandHPIVareprevalent. Conclusions: Viral respiratory infections in cancer patients are common and can worsen the patients’ condition and disrupt the treatment process. Therefore, prevention and treatment of respiratory viral infections in cancer patients is important. rhesus monkey (RMK), MRC-5 antibody (DFA) testing, viral culture and real time RT-PCR. Twenty-four influenza infected pediatric cancer patients (20 influenza A and 4 influenza B cases) 27 clinical","PeriodicalId":73510,"journal":{"name":"Iranian journal of cancer prevention","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46462340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号